David Shaw’s AnaptysBio ANAB Stock Holding History

David Shaw’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-23,500	Closed	-$2.45M	–	3677
2018 Q1	$2.45M	Buy	+23,500	New	+$2.65M	﹤0.01%	1919

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

David Shaw's ANAB Position: Q2 2026 in Review

David Shaw reduced its AnaptysBio (ANAB) stake by 6.8% in Q2 2026, selling an estimated $2.4M and leaving 539,666 shares worth $36.4M. The position accounts for 0.02% of the portfolio, ranked #942.

David Shaw first reported a position in ANAB in Q3 2017 and has held it in 30 quarters since. 211 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

David Shaw held 539,666 shares of AnaptysBio worth $36.4M as of Q2 2026.
David Shaw sold 39,630 AnaptysBio shares in Q2 2026, an estimated $2.4M.
AnaptysBio made up 0.02% of David Shaw's portfolio in Q2 2026, its #942 holding.
David Shaw first reported a position in AnaptysBio in Q3 2017 and has held it in 30 quarters since.
211 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.